Risk of uncomplicated peptic ulcer disease in a cohort of new users of low-dose acetylsalicylic acid for secondary prevention of cardiovascular events

BMC Gastroenterology

Luis A García Rodríguez¹  Mar Martín-Pérez¹  Péter Nagy²  Saga Johansson²  Ana Ruigómez¹ 

[1] Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Almirante 28-2, Madrid, E 28004, Spain;AstraZeneca R&D, Pepparedsleden 1, Mölndal SE-431 83, Sweden

关键词: Uncomplicated peptic ulcer disease;    Nested case–control study;    Acetylsalicylic acid;   

Others  :  1121746
DOI  :  10.1186/s12876-014-0205-y

 received in 2014-07-01, accepted in 2014-11-21,  发布年份 2014

【 摘 要 】

Background

The aim of this study was to analyse the risk of uncomplicated peptic ulcer disease (PUD) in a cohort of new users of low-dose acetylsalicylic acid (ASA) for secondary prevention of cardiovascular events in a UK primary care setting.

Methods

New users of low-dose ASA for secondary prevention of cardiovascular events, aged 50-84 years in 2000-2007, were identified from The Health Improvement Network. Among those 38,975 individuals, 309 patients were considered to be incident cases of uncomplicated PUD. Incidence of uncomplicated PUD was calculated and a nested case–control analysis adjusted for potential confounding factors was performed to calculate the odds ratios (ORs) for the association of potential risk factors with uncomplicated PUD.

Results

The crude incidence of uncomplicated PUD was 1.41 per 1000 person-years (95% confidence interval [CI], 1.26-1.58). Individuals with a history of PUD were more likely to develop uncomplicated PUD than those without such a history (hazard ratio [HR], 2.22, 95% CI, 1.60-3.09). In nested case–control analyses, the risk of uncomplicated PUD was associated with current use of non-steroidal anti-inflammatory drugs, oral steroids or acid suppressants. Other risk factors for developing uncomplicated PUD included smoking, stress, depression, anaemia and social deprivation.

Conclusion

Our results indicate that several risk factors significantly increase the risk of development of uncomplicated PUD in new users of low-dose ASA. Therefore, physicians should monitor ASA users for gastrointestinal symptoms and signs of ulcer, particularly if they have additional risk factors.

【 授权许可】

   
2014 Ruigomez et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP: ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012, 60:645-681.
• [2]Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte Op Reimer WJM, Vrints C, Wood D, Zamorano JL, Zannad F, Cooney MT, Bax J, Baumgartner H, et al.: European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701.
• [3]Cea Soriano L, García Rodríguez LA: Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes. Front Pharmacol 2010, 1:126-135.
• [4]García Rodríguez LA, Hernández-Díaz S: Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004, 159:23-31.
• [5]Barkun A, Leontiadis G: Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med 2010, 123:358-366. e352
• [6]Martín-Merino E, Johansson S, Bueno H, García Rodríguez LA: Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease. Prag Obs Res 2012, 3:1-9.
• [7]Pratt S, Thompson VJ, Elkin EP, Naesdal J, Sorstadius E: The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs 2010, 10:281-288.
• [8]Moberg C, Naesdal J, Svedberg L-E, Duchateau D, Harte N: Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic acid: a quantitative study in patients with cardiovascular risk. Patient 2011, 4:103-113.
• [9]Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G: Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey. Int J Cardiol 2012, 156:69-75.
• [10]Ferrari E, Benhamou M, Cerboni P, Marcel B: Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005, 45:456-459.
• [11]García Rodríguez LA, Cea-Soriano L, Martín-Merino E, Johansson S: Discontinuation of low dose aspirin and risk of myocardial infarction: case–control study in UK primary care. BMJ 2011, 343:d4094.
• [12]García Rodríguez LA, Cea Soriano L, Hill C, Johansson S: Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology 2011, 76:740-746.
• [13]Lassen A, Hallas J, Schaffalitzky de Muckadell OB: Complicated and uncomplicated peptic ulcers in a Danish county 1993–2002: a population-based cohort study. Am J Gastroenterol 2006, 101:945-953.
• [14]Hernández-Diaz S, Martín-Merino E, García Rodríguez LA: Risk of complications after a peptic ulcer diagnosis: effectiveness of proton pump inhibitors. Dig Dis Sci 2013, 58:1653-1662.
• [15]Miyake K, Kusunoki M, Ueki N, Nagoya H, Kodaka Y, Shindo T, Kawagoe T, Gudis K, Futagami S, Tsukui T, Nakamura H, Sakamoto C: Implication of antithrombotic agents on potential bleeding from endoscopically determined peptic ulcers, incidentally detected as surrogate markers for NSAIDs-associated ulcers complication. Dig Endosc 2013, 25:25-31.
• [16]Cai S, García Rodríguez LA, Massó-González EL, Hernández-Diaz S: Uncomplicated peptic ulcer in the UK: trends from 1997–2005. Aliment Pharmacol Ther 2009, 30:1039-1048.
• [17]Bourke A, Dattani H, Robinson M: Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004, 12:171-177.
• [18]Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL: Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007, 16:393-401.
• [19]Stuart-Buttle CD, Read JD, Sanderson HF, Sutton YM: A language of health in action: Read codes, classifications and groupings. Proc AMIA Annu Fall Symp 1996, ᅟ:75-79.
• [20]O’Neil M, Payne C, Read J: Read Codes Version 3: a user led terminology. Methods Inf Med 1995, 34:187-192.
• [21]In Practice Systems Ltd - Gemscript [http://www.resip.co.uk/gemscript]
• [22]Pilotto A, Franceschi M, Leandro G, Paris F, Cascavilla L, Longo MG, Niro V, Andriulli A, Scarcelli C, Di Mario F: Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004, 20:1091-1097.
• [23]Lau JY, Sung JJ, Metz DC, Howden CW: Systematic review of the epidemiology of complicated peptic ulcer: incidence, recurrence, risk factors and mortality. Gastroenterology 2008, 134(4 Suppl 1):A32.
• [24]García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S: Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011, 123:1108-1115.
• [25]Udd M, Miettinen P, Palmu A, Heikkinen M, Janatuinen E, Pasanen P, Tarvainen R, Mustonen H, Julkunen R: Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case–control study. Scand J Gastroenterol 2007, 42:1395-1403.
• [26]Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ: Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002, 16:497-506.
• [27]Lin KJ, Hernández-Diaz S, García Rodríguez LA: Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 2011, 141:71-79.
• [28]Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115:787-796.
• [29]Hernández-Díaz S, García Rodríguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000, 160:2093-2099.
• [30]Malmi H, Kautiainen H, Virta LJ, Farkkila N, Koskenpato J, Farkkila MA: Incidence and complications of peptic ulcer disease requiring hospitalisation have markedly decreased in Finland. Aliment Pharmacol Ther 2014, 39:496-506.
• [31]Blackburn DF, Lamb DA, McLeod MM, Eurich DT: Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies. Pharmacotherapy 2010, 30:985-993.
• [32]Yeomans ND: The ulcer sleuths: The search for the cause of peptic ulcers. J Gastroenterol Hepatol 2011, 26(Suppl 1):35-41.
• [33]Ford AC, Talley NJ: Does Helicobacter pylori really cause duodenal ulcers? Yes. BMJ 2009, 339:b2784.
• [34]Lin KJ, García Rodríguez LA, Hernández-Díaz S: Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf 2011, 20:718-728.